Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
G Ital Nefrol ; 37(3)2020 Jun 10.
Article in Italian | MEDLINE | ID: mdl-32530148

ABSTRACT

Valle d'Aosta, Italy's smallest region, faced a Covid-19 epidemic trend of absolute relevance. In line with data concerning the local general population, the predominance of the illness among uremic patients has been high. The authors report here preliminary data on the spread of this disease within the region and on the clinical trend of the infected patients who needed to be hospitalised.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Pandemics , Pneumonia, Viral/epidemiology , Renal Dialysis , Aged , Aged, 80 and over , COVID-19 , Data Analysis , Female , Global Health/statistics & numerical data , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , SARS-CoV-2 , Treatment Outcome
2.
G Ital Nefrol ; 37(1)2020 Feb 12.
Article in Italian | MEDLINE | ID: mdl-32068363

ABSTRACT

Atrial fibrillation is the most common cardiac disorder among chronic nephropathic patients. Possible therapeutic approaches include the use of anticoagulants, which are able to reduce the risk of thromboembolism but lead to an increasing bleeding risk, especially in this cohort of patients. Also, novel oral anticoagulant agents (NAO), due to their mainly renal clearance, are a relative contraindication in advanced renal disease. As an alternative to the oral anticoagulant therapy, left atrial appendage occlusion seems a promising opportunity in high risk, difficult to manage patients. Since there is limited evidence of LAAO in advanced chronic renal disease or dialysis patients, we report here a monocenter experience on 12 patients (6 of which in regular dialytic treatment) with a median clinical follow-up of fourteen months (3-22 months).


Subject(s)
Atrial Appendage , Atrial Fibrillation/complications , Renal Insufficiency, Chronic/complications , Therapeutic Occlusion/instrumentation , Thromboembolism/prevention & control , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Atrial Appendage/diagnostic imaging , Contraindications, Drug , Factor Xa Inhibitors/therapeutic use , Hemorrhage/chemically induced , Humans , Middle Aged , Prospective Studies , Prosthesis Design , Renal Dialysis , Renal Insufficiency, Chronic/therapy , Risk Assessment , Thromboembolism/etiology
3.
G Ital Nefrol ; 36(4)2019 Jul 24.
Article in Italian | MEDLINE | ID: mdl-31373468

ABSTRACT

In the last few years, the increasing awareness of the complex interaction between monoclonal component and renal damage has determined not only a new classification of the associated disorders, called Monoclonal Gammopathy of Renal Significance (MGRS), but has also contributed to emphasize the importance of an early diagnosis of the renal involvement, which is often hard to detect but can evolve towards terminal uraemia; it has also pointed at the need to treat these disorders with aggressive regimens, even if they are not strictly neoplastic. The case described here presented urinary abnormalities and renal failure secondary to a membranoproliferative glomerulonephritis (MPGN), with intensively positive immunofluorescence (IF) for monoclonal k light chain and C3, and in the absence of a neoplastic lympho-proliferative disorder documented on bone marrow biopsy. After the final diagnosis of MGRS, the patient was treated with several cycles of a therapy including dexamethasone, cyclophosphamide and bortezomib, showing a good functional and clinical response.


Subject(s)
Glomerulonephritis, Membranoproliferative/complications , Paraproteinemias/complications , Renal Insufficiency/etiology , Biopsy , Bortezomib/therapeutic use , Complement C3c , Cyclophosphamide/therapeutic use , Dexamethasone/therapeutic use , Early Diagnosis , Female , Glomerulonephritis, Membranoproliferative/diagnosis , Glomerulonephritis, Membranoproliferative/pathology , Glucocorticoids/therapeutic use , Humans , Immunoglobulin kappa-Chains , Kidney Glomerulus/pathology , Kidney Glomerulus/ultrastructure , Middle Aged , Paraproteinemias/drug therapy
4.
G Ital Nefrol ; 34(1)2017.
Article in Italian | MEDLINE | ID: mdl-28177096

ABSTRACT

Hyponatremia is the most common electrolyte disorder observed in hospitalized patients. The most severe forms are neurological and potentially fatal emergencies; yet increased morbidity, length of hospital stay and costs associated with less severe forms are aspects of major concern. Nephrologists are frequently consulted regarding the therapeutic management and the key pathophysiological issues of hyponatremia, as this latter aspect represents a true challenge in an emergency setting. We report a case of a woman admitted to the emergency room for gait instability caused by a very severe multifactorial hyponatremia with a favourable clinical outcome.


Subject(s)
Hyponatremia/etiology , Female , Humans , Hyponatremia/diagnosis , Middle Aged , Severity of Illness Index
5.
G Ital Nefrol ; 32(6)2015.
Article in Italian | MEDLINE | ID: mdl-26845210

ABSTRACT

Theophylline/aminophylline use for asthma and chronic obstructive pulmonary disease has declined over time, as new and safer therapies developed. However, theophylline/aminophylline overdose can occur. Hereby it is described an unusual case of severe aminophylline intoxication due to mesodermic injections treated with CVVHDF session.


Subject(s)
Aminophylline/poisoning , Acute Disease , Adult , Female , Humans
6.
G Ital Nefrol ; 31(6)2014.
Article in Italian | MEDLINE | ID: mdl-25504165

ABSTRACT

Lactic acidosis metformin-related is a potentially fatal complication. Reviews show a stable prevalence of this phenomenon, but nephrological experience is required since it is frequently involved in therapeutic management. Here we report the cases of two old patients with severe lactic acidosis and acute renal failure treated with hemodiafiltration.


Subject(s)
Acidosis, Lactic/chemically induced , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Aged, 80 and over , Female , Humans , Male
7.
G Ital Nefrol ; 27(6): 639-48, 2010.
Article in Italian | MEDLINE | ID: mdl-21132646

ABSTRACT

The treatment of membranous glomerulonephritis (MGN) is controversial, especially in cases of no response to first-line treatment or multiple relapses. The Clinical Nephrology Group of Piedmont carried out a multicenter analysis of the treatment of patients affected by MGN in 15 nephrology units in Piedmont. The first treatment is usually started after a waiting period of 3-6 months in case of proteinuria in the nephrotic range but normal or slightly impaired renal function. A history of cancer, the presence of infectious disease, and secondary forms of MGN are criteria for exclusion from treatment. As first-line treatment, Piedmont nephrologists prescribe corticosteroids alternated with immunosuppressive drugs, generally preferring cyclophosphamide to chlorambucil. Only one nephrology unit uses cyclosporin A (CyA) as the first choice. In case of no response to treatment, a second therapeutic approach is undertaken after 2-12 months. Second-line treatment consists of CyA if immunosuppressive drugs were given before, and corticosteroids/ immunosuppressive drugs if CyA was the first treatment. A further choice may be ACTH or rituximab. In case of multiple relapses the treatment options are the same but previous immunosuppressive treatment, patient age, and the duration of kidney disease with a greater probability of renal failure and progression towards sclerosis require careful attention. Concern has been expressed regarding the potentially severe side effects of ACTH including myopathy, cataract and diabetes. In conclusion, the applied therapeutic approaches in Piedmont reflect the difficulty reported in the literature in identifying simple recommendations. ACTH and rituximab are increasingly preferred for the treatment of MGN and there is a need for prospective studies to determine the best protocol for rituximab and the safety profile of ACTH.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Glomerulonephritis, Membranous/drug therapy , Guideline Adherence/statistics & numerical data , Immunosuppressive Agents/therapeutic use , Adrenocorticotropic Hormone/therapeutic use , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Chlorambucil/administration & dosage , Cyclophosphamide/administration & dosage , Cyclosporine/administration & dosage , Disease Progression , Drug Therapy, Combination , Glomerulonephritis, Membranous/diagnosis , Hormones/therapeutic use , Humans , Italy , Practice Guidelines as Topic , Rituximab , Treatment Outcome
8.
J Nephrol ; 23(1): 111-8, 2010.
Article in English | MEDLINE | ID: mdl-20091494

ABSTRACT

BACKGROUND: The aim of clinical risk management is to improve the quality of care provided by health care organizations and to assure patients' safety. Failure mode and effect analysis (FMEA) is a tool employed for clinical risk reduction. We applied FMEA to chronic hemodialysis outpatients. METHODS: FMEA steps: (i) process study: we recorded phases and activities. (ii) Hazard analysis: we listed activity-related failure modes and their effects; described control measures; assigned severity, occurrence and detection scores for each failure mode and calculated the risk priority numbers (RPNs) by multiplying the 3 scores. Total RPN is calculated by adding single failure mode RPN. (iii) Planning: we performed a RPNs prioritization on a priority matrix taking into account the 3 scores, and we analyzed failure modes causes, made recommendations and planned new control measures. (iv) Monitoring: after failure mode elimination or reduction, we compared the resulting RPN with the previous one. RESULTS: Our failure modes with the highest RPN came from communication and organization problems. Two tools have been created to ameliorate information flow: "dialysis agenda" software and nursing datasheets. We scheduled nephrological examinations, and we changed both medical and nursing organization. Total RPN value decreased from 892 to 815 (8.6%) after reorganization. CONCLUSIONS: Employing FMEA, we worked on a few critical activities, and we reduced patients' clinical risk. A priority matrix also takes into account the weight of the control measures: we believe this evaluation is quick, because of simple priority selection, and that it decreases action times.


Subject(s)
Equipment Failure Analysis/methods , Renal Dialysis/instrumentation , Risk Management/methods , Equipment Failure , Humans , Italy , Outpatients
9.
Nephrol Dial Transplant ; 19(9): 2341-6, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15252154

ABSTRACT

BACKGROUND: Late referral (LR) to the nephrologist of patients with progressing chronic kidney disease (CKD) has numerous deleterious effects and is observed in many countries. The contributing factors associated with LR are controversial and poorly defined. We hypothesized that these factors might be better identified by analysing patients starting dialysis in three distinct European countries within the same area. METHOD: The referral and progression of kidney failure patterns were analysed with demographic, clinical and biological data in 279 non-selected consecutive patients starting dialysis in eight centres of three adjacent regions in France, Italy and Switzerland. RESULTS: Early referral (>6 months before the start of dialysis) was seen in 200 patients (71.6%), intermediate referral (1-6 months) in 42 (15.1%) and LR (<1 month) in 37 (13.3%). However inter-centre variations were between 2 and 19% for LR and 6-50% for combined late and intermediate referral. There were no differences at the national levels, but LR was more frequent in the large city centres than in the private or regional structures, with 31 out of 169 (18.3%), two out of 55 (5.4%) and four out of 55 (7.3%), respectively, of their patients (P<0.01). By multivariate analysis, it appears that, besides the presence of an active cancer and the CKD progression rate, the centre structure and the referring physician (primary care physicians and nephrologists are less responsible for LR than other medical specialists) play a significant role in the practice of LR. CONCLUSIONS: Within a dialysis cohort spread over adjacent regions of three countries, LR has the same global distribution pattern, indicating that different health and social security systems do not play a major role in inducing or preventing this practice. The contributing factors for LR that were identified are the type of the referring physician and the structure of the dialysis unit. Both factors are potential targets for an educational and collaborative approach.


Subject(s)
Dialysis/statistics & numerical data , Kidney Failure, Chronic/therapy , Referral and Consultation/statistics & numerical data , Aged , Cohort Studies , Disease Progression , Europe/epidemiology , Humans , Middle Aged , Prospective Studies , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...